In last trading session, Replimune Group, Inc. (NASDAQ:REPL) saw 10,519,004 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $36.25 trading at $11.56 or 46.82% at ring of the bell on the day assigns it a market valuation of $1.46 Billion. That closing price of REPL’s stock is at a discount of -27.67% from its 52-week high price of $46.28 and is indicating a premium of 76.33% from its 52-week low price of $8.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 240.13 Million shares which gives us an average trading volume of 194.82 Million if we extend that period to 3-months.
For Replimune Group, Inc. (REPL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.9. Splitting up the data highlights that, out of 8 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.45 in the current quarter.
Replimune Group, Inc. (NASDAQ:REPL) trade information
Upright in the green today for gaining 46.82%, in the last five days REPL remained trading in the green while hitting it’s week-highest on Wednesday, Oct 14 when the stock touched $46.30- price level, adding 21.71% to its value on the day. Replimune Group, Inc.’s shares saw a change of 152.61% in year-to-date performance and have moved 45% in past 5-day. Replimune Group, Inc. (NASDAQ:REPL) showed a performance of 45.76% in past 30-days. Number of shares sold short was 933.53 Million shares which calculate 4.79 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $30.75 to the stock, which implies targetted prices is already lagging behind -15.17% to its current value. Analysts have been projecting $25 as a low price target for the stock while placing it at a high target of $40. It follows that stock’s current price would jump +10.34% in reaching the projected high whereas dropping to the targeted low would mean a loss of -31.03% for stock’s current value.
Replimune Group, Inc. (REPL) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -15.6% while estimates for its earnings growth in next 5 years are of 0%
Replimune Group, Inc. (NASDAQ:REPL)’s Major holders
Insiders are in possession of 15.51% of company’s total shares while institution are holding 88.94% percent of that, with stock having share float percentage of 105.27%. Investors also watch the number of corporate investors in a company very closely, which is 96 institutions for Replimune Group, Inc. that are currently holding shares of the company. Omega Fund Management (US) Inc. is the top institutional holder at REPL for having 5.34 Million shares of worth $132.82 Million. And as of June 29, 2020, it was holding 13.27% of the company’s outstanding shares.
The second largest institutional holder is Redmile Group, LLC, which was holding about 3.1 Million shares on June 29, 2020. The number of shares represents firm’s hold over 7.7% of outstanding shares, having a total worth of $77.14 Million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Victory Portfolios-Victory RS Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of July 30, 2020, the former fund manager was holding 918717 shares of worth $18.35 Million or 2.28% of the total outstanding shares. The later fund manager was in possession of 598.41 Thousand shares on June 29, 2020, making its stake of worth around $14.87 Million in the company or a holder of 1.49% of company’s stock.